ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Quercetin-loaded zinc oxide nanoparticles encapsulated in chitosan-alginate: a synergistic approach to cancer and bacterial therapy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ECSCR functions as a potential tumor suppressor in breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc oxide (ZnO) nanoparticles (NPs) exhibit promising antibacterial and anticancer properties. However, their cytotoxicity toward normal cells limits their therapeutic potential. To overcome this challenge, ZnO nanoparticles were loaded with quercetin (ZnO@Qc) and encapsulated within a chitosan-alginate composite, aiming to enhance their efficacy while reducing side effects. ZnO NPs were synthesized, characterized, and loaded with quercetin before being coated with a chitosan-alginate biopolymer. The antimicrobial activity was assessed through MIC and MBC assays against Gram-positive and Gram-negative bacteria. The cytotoxic effects were evaluated in HUVEC (normal) cells, and anticancer properties were analyzed in MCF-7 and MDA-MB-231 breast cancer cells using MTT, apoptosis (flow cytometry), scratch, and colony formation assays. Drug release kinetics were also studied at different pH levels. The chitosan-alginate-coated ZnO@Qc nanocomposite showed enhanced antibacterial activity, with lower MIC and MBC values compared to uncoated ZnO@Qc. The nanocomposite significantly reduced cytotoxicity toward normal HUVEC cells while maintaining strong anticancer effects, including dose-dependent inhibition of cell viability, apoptosis induction, and reduction in colony formation and cell migration. Gene expression analysis confirmed the upregulation of apoptotic markers (CASP3, CASP8, CASP9). Drug release studies demonstrated a controlled and pH-sensitive release of quercetin, favoring targeted delivery in the tumor microenvironment. The chitosan-alginate-coated ZnO@Qc system enhances antibacterial and anticancer efficacy while mitigating toxicity in normal cells. This multifunctional nanostructure holds promise for targeted breast cancer therapy and antimicrobial applications.
Indexed as
Identifiers
40459762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.